Q2 Earnings Forecast for DNLI Issued By William Blair

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at William Blair issued their Q2 2025 EPS estimates for shares of Denali Therapeutics in a report issued on Monday, July 7th. William Blair analyst M. Minter expects that the company will post earnings of ($0.80) per share for the quarter. William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. William Blair also issued estimates for Denali Therapeutics' Q3 2025 earnings at ($0.84) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.31) EPS, FY2026 earnings at ($3.70) EPS, FY2027 earnings at ($2.93) EPS and FY2028 earnings at ($0.56) EPS.

A number of other equities research analysts have also weighed in on DNLI. Robert W. Baird lowered their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Bank of America lowered their price target on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a report on Monday, May 19th. Cantor Fitzgerald upgraded shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. HC Wainwright lowered their price target on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Wedbush lowered their price target on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $33.71.

Denali Therapeutics Trading Down 5.4%

Shares of DNLI traded down $0.83 during mid-day trading on Wednesday, reaching $14.52. The company's stock had a trading volume of 1,691,789 shares, compared to its average volume of 1,139,362. The stock has a market cap of $2.11 billion, a PE ratio of -5.44 and a beta of 1.33. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $33.33. The company's fifty day moving average price is $14.25 and its two-hundred day moving average price is $16.57.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same period in the previous year, the company posted ($0.68) EPS.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 495,282 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the transaction, the chief executive officer directly owned 253,071 shares of the company's stock, valued at approximately $3,796,065. The trade was a 66.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 12.50% of the company's stock.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of DNLI. Caitong International Asset Management Co. Ltd grew its position in shares of Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock worth $29,000 after buying an additional 1,551 shares during the period. Sterling Capital Management LLC grew its position in shares of Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Denali Therapeutics in the 1st quarter worth about $41,000. GF Fund Management CO. LTD. purchased a new stake in shares of Denali Therapeutics in the 4th quarter worth about $62,000. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of Denali Therapeutics in the 4th quarter worth about $65,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.